DMII
Drugs Made In America Acquisition II Corp. Ordinary Shares
There isn't enough reported data to score DMII yet.
DMII Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Unavailable | |
| N/A | |
| N/A |
There isn't enough reported data to rate DMII's fundamentals.
DMII PE Valuation
DMII has no meaningful PE right now: it lost money over the past year.
DMII Forward outlook
There aren't enough analyst estimates for DMII to show an outlook.
DMII Earnings Per Share
DMII Quarterly Revenue
DMII Free Cash Flow
DMII Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -- |
| 1 year | 0% | -- |
DMII has 64M diluted shares, about the same as a year ago.
DMII Net Leverage
DMII Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 78.3 | Overbought |
| Stochastic | 49.5 | Neutral |
DMII's weekly RSI is 78 (overbought) and its Stochastic is 49 (neutral).
DMII PE vs Financial Services Sector
DMII has no meaningful PE right now: it lost money over the past year.
DMII Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $10.2 | 0.4% above |
| 20 week MA | $10.2 | 0.9% above |
| 50 week MA | $10.1 | 1.9% above |
DMII is in an uptrend: it's above all three of its weekly moving averages, and 1.9% above its 50-week average.
DMII Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2025 | $9.88 | $9.90 | +0.2% |
| 2026 YTD | $9.90 | $10.2 | +3.4% |
DMII has finished every year since 2025 higher, and it's up 3.4% so far in 2026.